Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation

Neurology

Volumn 81, Issue 17, 2013, Pages 1515-1522

  Wick, Wolfgang ^a,c   Meisner, Christoph ^e   Hentschel, Bettina ^f   Platten, Michael ^a   Schilling, Alissa ^a   Wiestler, Benedikt ^a,c   Sabel, Michael C ^a   Koeppen, Susanne ⁱ   Ketter, Ralf ^j   Weiler, Markus ^a,c,k   Tabatabai, Ghazaleh ^k   Von Deimling, Andreas ^b,d   Gramatzki, Dorothee ^k   Westphal, Manfred ^l   Schackert, Gabriele ^a,m   Loeffler, Markus ^f   Simon, Matthias ⁿ   Reifenberger, Guido ^g,h   Weller, Michael ^a  

^a Department of Neuro Oncology ^*  (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c German Cancer Consortium (DKTK)   (Australia)

^d Clinical Cooperation Unit Neuropathology   (Australia)

^e UNIVERSITY OF TÜBINGEN   (Germany)

^f UNIVERSITY OF LEIPZIG   (Germany)

^g HEINRICH HEINE UNIVERSITY   (Germany)

^h DKTK   (Germany)

ⁱ UNIVERSITY OF DUISBURG ESSEN   (Germany)

^j SAARLAND UNIVERSITY   (Germany)

^k UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^l UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^m DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

ⁿ UNIVERSITY OF BONN   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ISOCITRATE DEHYDROGENASE 1; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; DNA METHYLATION; GENE DELETION; GENE MUTATION; GLIOMA; HUMAN; MAJOR CLINICAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROMOTER REGION;

EID: 84888229904     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182a95680     Document Type: Article

References (32)

1. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003.
2. Reifenberger G, Hentschel B, Felsberg J, et al. Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. Int J Cancer 2012;131:1342-1350.
3. Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. J Clin Oncol 2009;27:5874-5880.
4. Van Den Bent MJ, Carpentier AF, Brandes AA, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 2006;24:2715-2722.
5. Van Den Bent MJ, Dubbink HJ, Sanson M, et al. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. J Clin Oncol 2009;27:5881-5886.
6. Noushmehr H, Weisenberger DJ, Diefes K, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010;17:510-522.
7. Weller M, Wick W, Von Deimling A. Isocitrate dehydrogenase mutations: a challenge to traditional views on the genesis and malignant progression of gliomas. Glia 2011;59:1200-1204.
8. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360:765-773.
9. Sanson M, Marie Y, Paris S, et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 2009;27:4150-4154.
10. Van Den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res 2010;16:1597-1604.
11. Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol 2009;27:5743-5750.
12. Sturm D, Witt H, Hovestadt V, et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 2012;22:425-437.
13. Hartmann C, Hentschel B, Tatagiba M, et al. Molecular markers in low-grade gliomas: predictive or prognostic? Clin Cancer Res 2011;17:4588-4599.
14. Kleihues P, Burger PC, Scheithauer BW. The new WHO classification of brain tumours. Brain Pathol 1993;3:255-268.
15. Kleihues P, Cavenee WK. Pathology and genetics of tumours of the nervous system. In: World Health Organization Classification of Tumours. Vol. 1. Lyon: IARC Press; 2000.
16. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97-109.
17. Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 2010;120:707-718.
18. Macdonald DR, Cascino TL, Schold SC Jr, et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-1280.
19. Wick W, Platten M, Meisner C, et al. Chemotherapy versus radiotherapy for malignant astrocytoma in the elderly. Lancet Oncol 2012;13:707-715.
20. Kaplan E, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
21. Esteller M. Epigenetics in cancer. N Engl J Med 2008;358:1148-1159.
22. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000;343:1350-1354.
23. Weller M, Stupp R, Reifenberger G, et al. MGMT promoter methylation in malignant gliomas: molecular neuropathology ready for personalized medicine? Nat Rev Neurol 2010;6:39-51.
24. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321:1807-1812.
25. Dubbink HJ, Taal W, Van Marion R, et al. IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. Neurology 2009;73:1792-1795.
26. Van Den Bent MJ, Brandes AA, Taphoorn M, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC Brain Tumor Group Study 26951. J Clin Oncol 2013;31:344-350.
27. Cairncross JG, Wang M, Shaw EG, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 94-02. J Clin Oncol 2013;31:337-343.
28. Turcan S, Rohle D, Goenka A, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012;483:479-483.
29. Lu C, Ward PS, Kapoor GS, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012;483:474-478.
30. Van Den Bent MJ, Gravendeel LA, Gorlia T, et al. A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC Study 26951. Clin Cancer Res 2011;17:7148-7155.
31. Malmström A, Gronberg BH, Marosi C, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomized, phase 3 trial. Lancet Oncol 2012;13:916-926.
32. Rivera AL, Pelloski CE, Gilbert MR, et al. MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro Oncol 2010;12:116-121.